CALT — Calliditas Therapeutics AB Share Price
Last trade - 00:00- $494.34m
- $493.69m
- SEK1.21bn
- 44
- 14
- 45
- 27
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 22.72 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 16.11 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 4.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -25.69% | ||
| Return on Equity | -84.68% | ||
| Operating Margin | -30.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | 184.83 | 0.87 | 229.35 | 802.88 | 1,206.89 | 1,983.04 | 3,577.58 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | +13847.38 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Calliditas Therapeutics AB, formerly Pharmalink AB, is a Sweden-based specialty pharmaceutical company. It is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
Directors
- Elmar Schnee NEC (62)
- Renee Aguiar-Lucander CEO (59)
- Fredrik Johansson CFO (44)
- Katayoun Welin-Berger VOP (53)
- Frank Bringstrup VPR (62)
- Warren Brooks VPR
- Andrew Udell VPR (51)
- David Ferraro OTH
- Teona Johnson OTH
- Richard Philipson OTH (57)
- Hilde Furberg NID (63)
- Lennart Hansson NID (63)
- Molly Henderson NID (51)
- Diane Parks NID (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 15th, 2004
- Public Since
- June 29th, 2018
- No. of Employees
- 181
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 53,672,069
- Address
- D5, Kungsbron 1,, STOCKHOLM, 111 22
- Web
- https://www.calliditas.se/
- Phone
- +46 84113005
- Contact
- Asa Hillsten
- Auditors
- Ernst & Young AB
Latest News for CALT
Similar to CALT
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Amylyx Pharmaceuticals
NASDAQ Global Select Market
Anika Therapeutics
NASDAQ Global Select Market
FAQ
As of Today at 19:04 UTC, shares in Calliditas Therapeutics AB are trading at $18.70. This share price information is delayed by 15 minutes.
Shares in Calliditas Therapeutics AB last closed at $18.70 and the price had moved by -21.43% over the past 365 days. In terms of relative price strength the Calliditas Therapeutics AB share price has underperformed the S&P500 Index by -34.62% over the past year.
The overall consensus recommendation for Calliditas Therapeutics AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Calliditas Therapeutics AB does not currently pay a dividend.
Calliditas Therapeutics AB does not currently pay a dividend.
Calliditas Therapeutics AB does not currently pay a dividend.
To buy shares in Calliditas Therapeutics AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $18.70, shares in Calliditas Therapeutics AB had a market capitalisation of $494.34m.
Here are the trading details for Calliditas Therapeutics AB:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: CALT
Based on an overall assessment of its quality, value and momentum Calliditas Therapeutics AB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Calliditas Therapeutics AB is $41.97. That is 124.43% above the last closing price of $18.70.
Analysts covering Calliditas Therapeutics AB currently have a consensus Earnings Per Share (EPS) forecast of SEK0.21 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Calliditas Therapeutics AB. Over the past six months, its share price has underperformed the S&P500 Index by -9.05%.
As of the last closing price of $18.70, shares in Calliditas Therapeutics AB were trading -3.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Calliditas Therapeutics AB PE ratio based on its reported earnings over the past 12 months is 22.72. The shares last closed at $18.70.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Calliditas Therapeutics AB's management team is headed by:
- Elmar Schnee - NEC
- Renee Aguiar-Lucander - CEO
- Fredrik Johansson - CFO
- Katayoun Welin-Berger - VOP
- Frank Bringstrup - VPR
- Warren Brooks - VPR
- Andrew Udell - VPR
- David Ferraro - OTH
- Teona Johnson - OTH
- Richard Philipson - OTH
- Hilde Furberg - NID
- Lennart Hansson - NID
- Molly Henderson - NID
- Diane Parks - NID